Shares of Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) traded up 4.7% during trading on Thursday . The stock traded as high as $13.38 and last traded at $13.38. 36,795 shares traded hands during mid-day trading, a decline of 84% from the average session volume of 227,627 shares. The stock had previously closed at $12.78.
Analysts Set New Price Targets
Several equities analysts recently issued reports on MAZE shares. Leerink Partners began coverage on shares of Maze Therapeutics in a report on Tuesday, February 25th. They set an "outperform" rating and a $28.00 price target for the company. JPMorgan Chase & Co. started coverage on Maze Therapeutics in a report on Tuesday, February 25th. They set an "overweight" rating and a $30.00 price target for the company. Leerink Partnrs upgraded Maze Therapeutics to a "strong-buy" rating in a report on Tuesday, February 25th. Guggenheim reaffirmed a "buy" rating and issued a $19.00 price target on shares of Maze Therapeutics in a report on Wednesday, April 2nd. Finally, TD Cowen raised shares of Maze Therapeutics to a "strong-buy" rating in a report on Tuesday, February 25th. Three analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus price target of $25.67.
Read Our Latest Research Report on MAZE
Maze Therapeutics Price Performance
The firm's 50 day moving average price is $10.02.
Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last posted its quarterly earnings results on Wednesday, May 14th. The company reported ($1.15) earnings per share for the quarter, missing the consensus estimate of ($0.76) by ($0.39).
Institutional Investors Weigh In On Maze Therapeutics
A number of institutional investors have recently made changes to their positions in MAZE. TRV GP IV LLC acquired a new position in Maze Therapeutics in the 1st quarter valued at $66,874,000. Frazier Life Sciences Management L.P. bought a new position in Maze Therapeutics during the first quarter worth about $45,460,000. ARCH Venture Management LLC acquired a new stake in Maze Therapeutics in the 1st quarter worth about $45,362,000. Matrix Capital Management Company LP bought a new stake in Maze Therapeutics in the 1st quarter valued at about $27,373,000. Finally, Alphabet Inc. acquired a new position in shares of Maze Therapeutics during the 1st quarter worth approximately $26,561,000.
About Maze Therapeutics
(
Get Free Report)
We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.
See Also
Before you consider Maze Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Maze Therapeutics wasn't on the list.
While Maze Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
